KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Share-based Compensation (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Share-based Compensation for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 22.67% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, down 22.62% year-over-year, with the annual reading at $7.0 million for FY2025, 22.62% down from the prior year.
  • Share-based Compensation hit $1.3 million in Q4 2025 for Arbutus Biopharma, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.6 million in Q1 2025 to a low of $864000.0 in Q2 2025.
  • Historically, Share-based Compensation has averaged $1.9 million across 5 years, with a median of $1.7 million in 2022.
  • Biggest YoY gain for Share-based Compensation was 76.96% in 2025; the steepest drop was 72.83% in 2025.
  • Year by year, Share-based Compensation stood at $1.4 million in 2021, then rose by 16.49% to $1.7 million in 2022, then grew by 3.36% to $1.7 million in 2023, then decreased by 5.28% to $1.6 million in 2024, then dropped by 22.67% to $1.3 million in 2025.
  • Business Quant data shows Share-based Compensation for ABUS at $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $864000.0 in Q2 2025.